Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of TMV-018 in Gastrointestinal Tumors
NCT04195373Phase 1Withdrawn
- Sponsor
- Themis Bioscience
- Start
- Nov 2020
- Primary completion
- Nov 2020
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TMV-018 in gastrointestinal cancer, colorectal cancer (CRC), esophageal cancer and 1 more (3 arms), sponsored by Themis Bioscience. Primary endpoints: Frequency of Adverse Events at 4 years and Maximum Tolerated Dose and Phase II Dose at 1.5 years. Planned start Nov 2020; status: withdrawn.
02
Drugs
TMV-018
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT04195373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195373.